Cerebrospinal Fluid Biomarkers for Huntington's Disease.

Cerebrospinal fluid (CSF) is enriched in brain-derived components and represents an accessible and appealing means of interrogating the CNS milieu to study neurodegenerative diseases and identify biomarkers to facilitate the development of novel therapeutics. Many such CSF biomarkers have been proposed for Huntington's disease (HD) but none has been validated for clinical trial use. Across many studies proposing dozens of biomarker candidates, there is a notable lack of statistical power, consistency, rigor and validation. Here we review proposed CSF biomarkers including neurotransmitters, transglutaminase activity, kynurenine pathway metabolites, oxidative stress markers, inflammatory markers, neuroendocrine markers, protein markers of neuronal death, proteomic approaches and mutant huntingtin protein itself. We reflect on the need for large-scale, standardized CSF collections with detailed phenotypic data to validate and qualify much-needed CSF biomarkers for clinical trial use in HD.

[1]  E. Budtz-Jørgensen,et al.  Ubiquitin: a potential cerebrospinal fluid progression marker in Huntington's disease , 2015, European journal of neurology.

[2]  Tormod Fladby,et al.  A Practical Guide to Immunoassay Method Validation , 2015, Front. Neurol..

[3]  M. Hayden,et al.  Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression , 2015, Scientific Reports.

[4]  Shing‐Jong Huang,et al.  On supplementary information , 2012, Nature Immunology.

[5]  S. Tabrizi,et al.  Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. , 2015, The Journal of clinical investigation.

[6]  J. Toldi,et al.  Changing the Face of Kynurenines and Neurotoxicity: Therapeutic Considerations , 2015, International journal of molecular sciences.

[7]  Henrik Zetterberg,et al.  CSF biomarkers and clinical progression of Parkinson disease , 2015, Neurology.

[8]  G. Kroemer Autophagy: a druggable process that is deregulated in aging and human disease. , 2015, The Journal of clinical investigation.

[9]  E. Budtz-Jørgensen,et al.  YKL-40 in cerebrospinal fluid in Huntington's disease--a role in pathology or a nonspecific response to inflammation? , 2014, Parkinsonism & related disorders.

[10]  S. Tabrizi,et al.  Targets for future clinical trials in Huntington's disease: What's in the pipeline? , 2014, Movement disorders : official journal of the Movement Disorder Society.

[11]  N. Dantuma,et al.  The ubiquitin-proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solution , 2014, Front. Mol. Neurosci..

[12]  Jane S. Paulsen,et al.  Huntington disease: natural history, biomarkers and prospects for therapeutics , 2014, Nature Reviews Neurology.

[13]  S. Tabrizi,et al.  HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation. , 2014, Brain : a journal of neurology.

[14]  Nick C Fox,et al.  Identification of an important potential confound in CSF AD studies: aliquot volume , 2013, Clinical chemistry and laboratory medicine.

[15]  Chris Frost,et al.  Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data , 2013, The Lancet Neurology.

[16]  H. Zetterberg,et al.  Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease , 2013, Current opinion in psychiatry.

[17]  J. Toldi,et al.  Kynurenines in the CNS: recent advances and new questions , 2012, Nature Reviews Drug Discovery.

[18]  S. Tabrizi,et al.  Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. , 2012, The Journal of clinical investigation.

[19]  S. Tabrizi,et al.  Biomarkers for Huntington's disease: an update. , 2012, Expert opinion on medical diagnostics.

[20]  J. Kong,et al.  Oxidative stress in neurodegenerative diseases , 2012, Neural regeneration research.

[21]  Chris Frost,et al.  Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data , 2012, The Lancet Neurology.

[22]  Megan M. Romer,et al.  Increased levels of total tau protein in the cerebrospinal fluid in Huntington's disease. , 2011, Parkinsonism & related disorders.

[23]  Yih-Ru Wu,et al.  Increased Prothrombin, Apolipoprotein A-IV, and Haptoglobin in the Cerebrospinal Fluid of Patients with Huntington's Disease , 2011, PloS one.

[24]  G. Halliday,et al.  Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses , 2010, Acta Neuropathologica.

[25]  R. Schwarcz,et al.  Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington’s disease , 2010, Journal of neurochemistry.

[26]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[27]  Å. Petersén The Role of Hypothalamic and Neuroendocrine Changes in the Pathogenesis of Huntington’s Disease - Current Understanding and Implications for Future Treatments , 2010 .

[28]  Megan M. Romer,et al.  Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington's disease. , 2009, Parkinsonism & related disorders.

[29]  Damon H. May,et al.  Brain-specific Proteins Decline in the Cerebrospinal Fluid of Humans with Huntington Disease , 2009, Molecular & Cellular Proteomics.

[30]  M. Hayden,et al.  A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease , 2008, The Journal of experimental medicine.

[31]  W. Matson,et al.  Increased levels of γ‐glutamylamines in Huntington disease CSF , 2008, Journal of neurochemistry.

[32]  Sarah J Tabrizi,et al.  Biomarkers for Huntington's disease. , 2008, Expert opinion on medical diagnostics.

[33]  J. Jankovic,et al.  Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. , 2008, Archives of neurology.

[34]  B. Leavitt,et al.  Cocaine‐ and amphetamine‐regulated transcript is increased in Huntington disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[35]  Alexandra Durr,et al.  Early Energy Deficit in Huntington Disease: Identification of a Plasma Biomarker Traceable during Disease Progression , 2007, PloS one.

[36]  S. Tabrizi,et al.  Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. , 2007, Journal of proteome research.

[37]  S. Calza,et al.  Low brain‐derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[38]  M. Hayden,et al.  Cerebrospinal fluid levels of orexin‐A are not a clinically useful biomarker for Huntington disease , 2006, Clinical genetics.

[39]  Juan Manuel Maler,et al.  Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. , 2006, Clinical chemistry.

[40]  Larry J Kricka,et al.  Nanotechnologic nutraceuticals: nurturing or nefarious? , 2006, Clinical chemistry.

[41]  E. Mignot,et al.  CSF hypocretin levels are normal in Huntington's disease patients. , 2005, Sleep.

[42]  B. Mollenhauer,et al.  Normal hypocretin-1 (orexin-A) levels in the cerebrospinal fluid of patients with Huntington's disease , 2005, Brain Research.

[43]  J. Kaye,et al.  Safety and Acceptability of the Research Lumbar Puncture , 2005, Alzheimer disease and associated disorders.

[44]  H. Aburatani,et al.  Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. , 2005, Genomics.

[45]  F. Casanueva,et al.  Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease. , 2004, European journal of endocrinology.

[46]  M. Alessio,et al.  Proteome study of human cerebrospinal fluid following traumatic brain injury indicates fibrin(ogen) degradation products as trauma-associated markers. , 2004, Journal of neurotrauma.

[47]  E. Giacobini,et al.  Cerebrospinal fluid acetylcholinesterase and choline measurements in Huntington's disease , 1990, Journal of Neurology.

[48]  G. Oepen,et al.  Huntington's Disease — Imbalance of free amino acids in the cerebrospinal fluid of patients and offspring at-risk , 2004, Archiv für Psychiatrie und Nervenkrankheiten.

[49]  H. Reiber Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics. , 2003, Restorative neurology and neuroscience.

[50]  Ruoyan Chen,et al.  Brain-derived Neurotrophic Factor Is Stored in Human Platelets and Released by Agonist Stimulation , 2002, Thrombosis and Haemostasis.

[51]  J. Blass,et al.  Cross linking of polyglutamine domains catalyzed by tissue transglutaminase is greatly favored with pathological-length repeats: does transglutaminase activity play a role in (CAG) n /Q n -expansion diseases? , 2002, Neurochemistry International.

[52]  M. Beal,et al.  N ε ‐(γ‐l‐Glutamyl)‐l‐lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease , 2001 .

[53]  T. Montine,et al.  Cerebrospinal fluid F2-isoprostanes are elevated in Huntington’s disease , 1999, Neurology.

[54]  T. Montine,et al.  Cerebrospinal fluid F2‐isoprostane levels are increased in Alzheimer's disease , 1998, Annals of neurology.

[55]  Jeffry D. Madura,et al.  Homology Modeling of Glycosyl Hydrolase Family 18 Enzymes and Proteins , 1997, J. Chem. Inf. Comput. Sci..

[56]  Jane S. Paulsen,et al.  Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.

[57]  L. Pantoni,et al.  Abnormal penetration of haptoglobin through the blood-brain-barrier (BBB) into the cerebro-spinal fluid (CSF) in Alzheimer's disease patients. , 1995, Acta Neurologica Scandinavica.

[58]  M. Mena,et al.  Cerebrospinal fluid homovanillic acid is reduced in untreated Huntington's disease. , 1995, Clinical neuropharmacology.

[59]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[60]  M. Demitrack,et al.  Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. , 1992, Brain : a journal of neurology.

[61]  P. Soares-da-Silva,et al.  Increased Cerebrospinal Fluid Dopamine and 3,4‐Dihydroxyphenylacetic Acid Levels in Huntington's Disease: Evidence for an Overactive Dopaminergic Brain Transmission , 1992, Journal of neurochemistry.

[62]  M. Beal,et al.  Regional brain and cerebrospinal fluid quinolinic acid concentrations in Huntington's disease , 1991, Neuroscience Letters.

[63]  M. Beal,et al.  Kynurenine Pathway Measurements in Huntington's Disease Striatum: Evidence for Reduced Formation of Kynurenic Acid , 1990, Journal of neurochemistry.

[64]  R. Schwarcz,et al.  Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia , 1988, Annals of neurology.

[65]  J. Coyle,et al.  Cerebrospinal fluid correlates of depression in Huntington's disease. , 1988, Archives of neurology.

[66]  B. Manyam,et al.  Isoniazid-induced alteration of CSF neurotransmitter amino acids in Huntington's disease , 1987, Brain Research.

[67]  Y. Agid,et al.  Cerebrospinal fluid GABA and homocarnosine concentrations in patients with Friedreich's ataxia, Parkinson's disease, and Huntington's chorea , 1987, Movement disorders : official journal of the Movement Disorder Society.

[68]  C. Kilts,et al.  Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. , 1984, Science.

[69]  B. Manyam,et al.  Isoniazid‐induced elevation of CSF GABA levels and effects on chorea in huntington's disease , 1981, Annals of neurology.

[70]  Y. Agid,et al.  Treatment of Huntington disease with gamma-acetylenic GABA an irreversible inhibitor of GABA-transaminase: increased CSF GABA and homocarnosine without clinical amelioration. , 1981, Neurology.

[71]  T. Hare,et al.  Effect of isoniazid on cerebrospinal fluid and plasma GABA levels in Huntington's disease. , 1980, Life sciences.

[72]  Y. Agid,et al.  Cerebrospinal fluid homocarnosine in Huntington's disease. , 1980, Life sciences.

[73]  F. Goodwin,et al.  Cerebrospinal Fluid Studies of Neurotransmitter Function in Manic and Depressive Illness , 1980 .

[74]  T. Hare,et al.  Huntington's disease. Cerebrospinal fluid GABA levels in at-risk individuals. , 1978, Archives of neurology.

[75]  L. Stern,et al.  Cerebrospinal fluid gamma-aminobutyric acid variations in neurological disorders. , 1977, Archives of neurology.

[76]  S. Snyder,et al.  γ‐Aminobutyric acid (GABA) in human cerebrospinal fluid: radioreceptor assay , 1977, Journal of neurochemistry.

[77]  S. Persson,et al.  CEREBROSPINAL HOMOVANILLIC ACID AND 5‐HYDROXYINDOLEACETIC ACID IN HUNTINGTON'S CHOREA , 1974, Acta psychiatrica Scandinavica. Supplementum.

[78]  D. Sharpe,et al.  Amine metabolites in the cerebrospinal fluid in Huntington's chorea , 1972 .

[79]  H. Klawans Cerebrospinal fluid homovanillic acid in Huntington's chorea. , 1971, Journal of the neurological sciences.

[80]  H. Klawans,et al.  A pharmacologic analysis of Huntington's chorea. , 1970, European neurology.